Amrutanjan Health Care Ltd

₹ 700 -0.81%

22 Nov - close price

amrutanjan.com BSE: 590006 NSE: AMRUTANJAN

About

AHCL has been manufacturing ayurvedic balm for pain management since 1893, and is currently managed by the third-generation of promoters. The company is more than 120 years old and is into OTC products in the segments of pain management, women's hygiene, and packaged fruit juice drink. ^[1]

Key Points

High Market Share in Modern Trade
Amrutanjan has maintained the No. 1 rank in Modern Trade in Head Category with the volume market share of 41.1%* in CY19. ^[1]

Website BSE NSE

Market Cap ₹ 2,023 Cr.
Current Price ₹ 700
High / Low ₹ 863 / 556
Stock P/E 42.6
Book Value ₹ 103
Dividend Yield 0.66 %
ROCE 21.3 %
ROE 15.5 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 27.8%

Cons

Promoter holding has decreased over last quarter: -4.07%
The company has delivered a poor sales growth of 10.7% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
	110	111	107	71	111	98	100	78	99	117	127	84	110
	87	85	90	68	95	85	87	71	92	95	111	80	96
Operating Profit	23	26	16	3	16	12	13	7	7	22	16	4	14
OPM %	21%	23%	15%	5%	14%	12%	13%	9%	7%	18%	13%	4%	12%
	4	3	5	3	3	4	5	4	4	4	5	4	4
Interest	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1	1	1	1	2	1	1	1	2	2	2	2	2
Profit before tax	26	28	20	5	17	15	16	9	9	24	20	6	16
Tax %	25%	26%	27%	30%	27%	26%	23%	26%	26%	26%	30%	27%	26%
	20	21	15	4	13	11	13	7	7	17	14	5	12
EPS in Rs	6.79	7.04	5.03	1.25	4.37	3.66	4.34	2.40	2.37	6.04	4.72	1.60	4.08
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
	128	131	154	174	207	220	253	261	333	406	380	421	438
	109	108	130	143	178	192	222	231	258	326	335	369	383
Operating Profit	19	23	25	32	29	28	31	31	75	80	45	52	55
OPM %	15%	18%	16%	18%	14%	13%	12%	12%	22%	20%	12%	12%	13%
	4	3	5	6	7	8	7	8	11	15	15	16	17
Interest	2	2	1	0	0	0	0	0	1	1	0	0	0
Depreciation	3	3	2	3	2	3	3	4	4	4	5	6	6
Profit before tax	18	21	26	35	34	33	35	34	82	91	54	62	66
Tax %	32%	32%	35%	35%	35%	39%	29%	27%	25%	26%	26%	27%
	12	15	17	22	22	20	25	25	61	67	40	45	48
EPS in Rs	4.15	4.97	5.86	7.68	7.47	6.84	8.39	8.58	20.93	22.99	13.63	15.55	16.44
Dividend Payout %	36%	32%	30%	25%	26%	22%	26%	24%	20%	20%	34%	30%

Compounded Sales Growth
10 Years:	12%
5 Years:	11%
3 Years:	8%
TTM:	17%

Compounded Profit Growth
10 Years:	11%
5 Years:	13%
3 Years:	-10%
TTM:	28%

Stock Price CAGR
10 Years:	12%
5 Years:	9%
3 Years:	-8%
1 Year:	14%

Return on Equity
10 Years:	20%
5 Years:	21%
3 Years:	19%
Last Year:	15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	3	3	3	3	3	3	3	3	3	3	3	3	3
Reserves	85	94	102	118	113	126	143	156	213	262	288	286	295
	13	6	0	0	2	0	0	2	1	1	1	2	2
	26	22	25	28	34	38	42	44	57	84	70	77	83
Total Liabilities	127	124	130	149	152	166	188	205	274	350	362	367	383
	17	15	13	22	27	28	26	26	23	28	49	50	51
CWIP	1	1	4	1	1	0	0	0	2	17	1	2	1
Investments	30	14	14	10	10	8	18	18	18	13	5	0	0
	79	95	100	116	115	131	144	161	232	291	307	315	331
Total Assets	127	124	130	149	152	166	188	205	274	350	362	367	383

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
	8	18	19	21	8	19	21	18	91	52	20	28
	16	16	-5	1	-0	-8	-11	-14	-88	-36	-2	19
	-17	-14	-12	-11	-5	-9	-7	-12	-7	-17	-15	-48
Net Cash Flow	8	20	2	12	3	2	3	-7	-4	-1	3	-1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	78	66	62	55	51	46	47	37	19	34	32	42
Inventory Days	44	45	44	44	44	40	45	74	45	53	58	50
Days Payable	55	44	46	51	110	102	92	98	106	122	95	96
Cash Conversion Cycle	67	67	61	48	-15	-16	0	13	-41	-35	-6	-5
Working Capital Days	57	54	42	45	80	26	30	71	29	92	117	173
ROCE %	20%	24%	26%	29%	28%	25%	25%	23%	44%	38%	19%	21%

Shareholding Pattern

Numbers in percentages

7 Recently

	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
	50.02%	50.02%	50.02%	50.02%	50.02%	50.03%	50.03%	50.59%	50.59%	50.59%	50.58%	46.52%
	1.83%	1.43%	1.42%	0.87%	0.76%	0.68%	0.69%	0.75%	0.80%	1.38%	1.55%	2.34%
	6.14%	6.14%	6.16%	6.30%	6.39%	7.18%	7.22%	7.10%	7.24%	7.29%	7.32%	10.60%
	41.90%	42.23%	42.21%	42.62%	42.65%	41.93%	41.87%	41.39%	41.19%	40.66%	40.47%	40.50%
	0.11%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.18%	0.07%	0.07%	0.04%
No. of Shareholders	61,367	67,323	66,173	71,064	72,104	69,947	71,428	72,002	68,404	62,664	57,169	54,536

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
	50.09%	50.02%	50.02%	50.02%	50.02%	50.02%	50.03%	50.59%	46.52%
	0.31%	1.09%	1.93%	4.69%	2.00%	1.43%	0.68%	1.38%	2.34%
	2.79%	5.68%	8.73%	8.12%	7.76%	6.14%	7.18%	7.29%	10.60%
	46.80%	43.20%	39.32%	37.17%	40.16%	42.23%	41.93%	40.66%	40.50%
	0.00%	0.00%	0.00%	0.00%	0.06%	0.18%	0.18%	0.07%	0.04%
No. of Shareholders	18,427	16,140	18,226	21,207	29,474	67,323	69,947	62,664	54,536

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Nov 2024

Transcript

Notes
PPT
Aug 2024

Transcript

Notes
PPT
May 2024

Transcript

Notes
PPT
Feb 2024

Transcript

Notes
PPT
Nov 2023

Transcript

Notes
PPT
Aug 2023

Transcript

Notes
PPT
Jun 2023

Transcript

Notes
PPT
Feb 2023

Transcript

Notes
PPT
Nov 2022

Transcript

Notes
PPT
Aug 2022

Transcript

Notes
PPT
May 2022

Transcript

Notes
PPT
Feb 2022

Transcript

Notes
PPT
Nov 2021

Transcript

Notes
PPT
Aug 2021

Transcript

Notes
PPT
May 2021

Transcript

Notes
PPT
Feb 2021

Transcript

Notes
PPT
Nov 2020

Transcript

Notes
PPT
Aug 2020

Transcript

Notes
PPT
Jun 2020

Transcript

Notes
PPT
Feb 2020

Transcript

Notes
PPT
Feb 2020

Transcript

Notes
PPT
Nov 2019

Transcript

Notes
PPT
Aug 2019

Transcript

Notes
PPT
May 2019

Transcript

Notes
PPT